Venetoclax in acute myeloid leukemia

被引：3
|
作者：
Bruzzese, Antonella [1 ,5 ]
Martino, Enrica Antonia [1 ]
Mendicino, Francesco [1 ]
Lucia, Eugenio [1 ]
Olivito, Virginia [1 ]
Neri, Antonino [2 ]
Morabito, Fortunato [3 ]
Vigna, Ernesto [1 ]
Gentile, Massimo [1 ,4 ,5 ]
机构：
[1] Azienda Osped Annunziata, Hematol Unit, Cosenza, Italy
[2] Sci Directorate IRCCS Reggio Emilia, Reggio Emilia, Italy
[3] AO Cosenza, Biotechnol Res Unit, Cosenza, Italy
[4] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy
[5] AO Cosenza, Hematol Unit, Viale Repubbl Snc, I-87100 Cosenza, Italy
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2023年 / 32卷 / 04期
关键词：
Venetoclax; AML; therapy; INTENSIVE CHEMOTHERAPY; SINGLE-CENTER; CELL-DEATH; CYTARABINE; RESISTANCE; DAUNORUBICIN; AZACITIDINE; COMBINATION; INHIBITION; ABT-199;
D O I：
10.1080/13543784.2023.2193679
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：271 / 276
页数：6
相关论文
共 50 条
  • [1] Venetoclax in Acute Myeloid Leukemia
    Mihaila, Romeo G.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2023, 18 (01) : 11 - 28
  • [2] Venetoclax Resistance in Acute Myeloid Leukemia
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Collette, Yves
    Vey, Norbert
    CANCERS, 2024, 16 (06)
  • [3] Venetoclax in adult acute myeloid leukemia
    Hu, Mengci
    Li, Wenzhe
    Zhang, Youshan
    Liang, Caixia
    Tan, Jie
    Wang, Ya
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [4] Combined venetoclax and alvocidib in acute myeloid leukemia
    Bogenberger, James
    Whatcott, Clifford
    Hansen, Nanna
    Delman, Devora
    Shi, Chang-Xin
    Kim, Wontak
    Haws, Hillary
    Soh, Katherine
    Lee, Ye Sol
    Peterson, Peter
    Siddiqui-Jain, Adam
    Weitman, Steven
    Stewart, Keith
    Bearss, David
    Mesa, Ruben
    Warner, Steven
    Tibes, Raoul
    ONCOTARGET, 2017, 8 (63): : 107206 - 107222
  • [5] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [6] Prescription patterns of venetoclax in acute myeloid leukemia
    Ucciero, Andrealuna
    Traversa, Giuseppe
    Pisterna, Alessia
    Cardinali, Valeria
    Sciabolacci, Sofia
    Poloni, Antonella
    Capelli, Debora
    Gaidano, Gianluca
    Patriarca, Andrea
    Lunghi, Monia
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
  • [7] Venetoclax for every patient diagnosed with acute myeloid leukemia?
    Cailly, Laura
    Gallego-Hernanz, Maria-Pilar
    Torregrosa-Diaz, Jose-Miguel
    HEMATOLOGIE, 2022, 28 (01): : 6 - 8
  • [8] Venetoclax-based therapies for acute myeloid leukemia
    Guerra, Veronica A.
    DiNardo, Courtney
    Konopleva, Marina
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 145 - 153
  • [9] Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
    Rodriguez-Medina, Carlos
    Stuckey, Ruth
    Bilbao-Sieyro, Cristina
    Gomez-Casares, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [10] Outpatient initiation of venetoclax in patients with acute myeloid leukemia
    Palmer, Shannon
    Patel, Anand
    Wang, Christopher
    Patel, Bianka
    Zeidner, Joshua
    Foster, Matthew
    Muluneh, Benyam
    Buhlinger, Kaitlyn
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1590 - 1598
12345